Related Experiment Video
Updated: Feb 3, 2026

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact
J F García-Rodríguez1, B Bardán-García2, M F Peña-Rodríguez3
1Infectious Diseases Unit. Department of Internal Medicine, University Hospital of Ferrol, Sergas, Ferrol, 15405, La Coruña, Spain. jose.francisco.garcia.rodriguez@sergas.es.
Implementing a meropenem antibiotic stewardship program (ASP) significantly improved meropenem prescription adequacy and reduced consumption. This led to decreased hospital-acquired multidrug-resistant bloodstream infections and lower mortality rates.
Area of Science:
- Infectious Diseases
- Antimicrobial Stewardship
- Public Health
Background:
- Limited prospective studies evaluate the long-term clinical and antibiotic resistance impact of antibiotic stewardship programs (ASPs).
- Meropenem is a critical broad-spectrum antibiotic, necessitating careful stewardship to preserve efficacy and minimize resistance.
- Hospital-acquired multidrug-resistant (MDR) bloodstream infections (BSIs) pose a significant threat to patient outcomes and healthcare costs.
Purpose of the Study:
- To evaluate the clinical, economic, and ecological impact of a meropenem-focused antibiotic stewardship program (ASP).
- To assess changes in meropenem prescription adequacy, consumption, and associated outcomes, including MDR BSIs and mortality.
- To analyze factors associated with intervention acceptance and their impact on patient care.
Main Methods:
- A descriptive, pre-post intervention study conducted from January 2012 to December 2017.
- Implementation of a meropenem ASP in January 2015, involving infectious disease physician recommendations.
- Prospective data collection on meropenem prescription adequacy, intervention acceptance, meropenem consumption, MDR BSIs, and 30-day mortality.
Main Results:
- Meropenem prescription adequacy and de-escalation to narrower-spectrum antibiotics improved significantly post-ASP implementation (p < 0.001).
- Meropenem consumption decreased by 33% (RR 0.67) during 2015-2017 compared to 2012-2014 (p < 0.001).
- Hospital-acquired MDR BSI rates decreased (RR 0.63, p=0.048), and 30-day mortality in MDR BSIs showed a downward trend (RR 0.45, p=0.096).
Conclusions:
- The meropenem ASP demonstrated sustained clinical, economic, and ecological benefits.
- Improved meropenem use led to reduced costs and mortality associated with hospital-acquired MDR BSIs.
- ASP interventions were accepted in most cases and associated with positive patient outcomes.
More Related Videos
Related Concept Videos
Development of Antibiotic Resistance
Antibiotic Selection
Antimicrobial Effectiveness
Impact of Groups on Groups
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Resistivity

